Frankfurt - Delayed Quote EUR
Telix Pharmaceuticals Limited (T3X.F)
16.89
+1.09
+(6.93%)
At close: 4:56:36 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
637,078
783,207
502,547
160,096
4,898
Cost of Revenue
233,316
273,529
188,157
65,170
2,548
Gross Profit
403,762
509,678
314,390
94,926
2,350
Operating Expense
324,176
428,224
262,523
169,122
101,150
Operating Income
79,586
81,454
51,867
-74,196
-98,800
Net Non Operating Interest Income Expense
-14,388
-26,074
-12,745
-6,692
-5,218
Other Income Expense
-25,570
676
-36,027
-17,734
23,553
Pretax Income
50,069
56,056
3,087
-98,622
-80,465
Tax Provision
884
6,137
-2,124
5,457
45
Net Income Common Stockholders
49,185
49,919
5,211
-104,079
-80,510
Diluted NI Available to Com Stockholders
--
49,919
5,211
-104,079
--
Basic EPS
0.15
0.15
0.02
-0.34
-0.28
Diluted EPS
0.15
0.14
0.02
-0.34
-0.28
Basic Average Shares
324,233.29
331,226
319,181
310,644
282,206
Diluted Average Shares
329,821.38
345,188
323,710
310,644
282,206
Total Operating Income as Reported
--
82,130
15,840
-91,930
--
Rent Expense Supplemental
--
4,250
3,411
2,097
1,754
Total Expenses
--
701,753
450,680
234,292
103,698
Net Income from Continuing & Discontinued Operation
49,185
49,919
5,211
-104,079
-80,510
Normalized Income
49,974.80
49,710.62
30,444.60
-91,601.50
-81,698.60
Interest Income
1,939
10,862
1,019
1
--
Interest Expense
15,650
36,491
13,558
6,610
5,218
Net Interest Income
-14,388
-26,074
-12,745
-6,692
-5,218
EBIT
65,719
92,547
16,645
-92,012
-75,247
EBITDA
72,966
92,547
16,645
-92,012
-70,073
Reconciled Cost of Revenue
233,316
273,529
188,157
65,170
2,548
Reconciled Depreciation
7,247
--
6,743
5,379
5,174
Net Income from Continuing Operation Net Minority Interest
49,185
49,919
5,211
-104,079
-80,510
Total Unusual Items Excluding Goodwill
-804
234
-36,048
-17,825
1,698
Total Unusual Items
-804
234
-36,048
-17,825
1,698
Normalized EBITDA
73,770
92,313
52,693
-74,187
-71,771
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-14.20
25.62
-10,814.40
-5,347.50
509.40
12/31/2021 - 7/17/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ASPHF Ascentage Pharma Group International
5.83
0.00%
BEAM.MX Beam Therapeutics Inc.
390.00
+4.18%
ADAG Adagene Inc.
1.3900
-2.80%
AAPG Ascentage Pharma Group Internat
25.50
+6.69%
BCTXW BriaCell Therapeutics Corp.
0.1706
+36.48%
SER Serina Therapeutics, Inc.
6.09
+5.36%
RNTX Rein Therapeutics Inc.
1.8300
+0.55%
MBX MBX Biosciences, Inc.
9.27
+3.11%
DSGN Design Therapeutics, Inc.
4.2400
+4.18%
BCAX Bicara Therapeutics Inc.
15.63
+0.77%